Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM Debt-to-EBITDA is -96.60 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, NovelStem International ranks better than 71.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for NovelStem International's Debt-to-EBITDA or its related term are showing as below:
NSTM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.34 Med: -0.05 Max: 0.72
Current: 0.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of NovelStem International was 0.72. The lowest was -4.34. And the median was -0.05.
NSTM's Debt-to-EBITDA is ranked better than 71.93% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs NSTM: 0.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
NovelStem International Debt-to-EBITDA Related Terms
NovelStem International Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSTM vs NOTVQ, PRPH, IDTA: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, NovelStem International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NovelStem International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
NovelStem International (NSTM) has a Debt-to-EBITDA of -96.60 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NovelStem International. According to the industry distribution chart, NovelStem International ranks #32 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 28.1%.
Is NovelStem International's Debt-to-EBITDA too high?
NovelStem International's current Debt-to-EBITDA is -96.60. Based on the distribution chart, NovelStem International ranks #32 out of 114 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does NovelStem International's Debt-to-EBITDA compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #32 out of 114 companies for Debt-to-EBITDA. This puts NovelStem International in the upper half of its industry. The industry median Debt-to-EBITDA is 2.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on NovelStem International. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current Debt-to-EBITDA is -96.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Debt-to-EBITDA of -96.60. The current Debt-to-EBITDA is -96.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For NovelStem International (NSTM), the current Debt-to-EBITDA is -96.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
